These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 8015704)

  • 1. [Treatment with GnRH analogs in polycystic ovarian disease. A collaborative multicenter study. The preliminary results].
    Cipolla L; Zagni R; Ferrante B; Giannetta G; Soliani A
    Minerva Ginecol; 1994 Mar; 46(3):85-9. PubMed ID: 8015704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gonadotropin-releasing hormone agonists administration in polycystic ovary syndrome. Effects on bone mass.
    Lupoli G; Di Carlo C; Nuzzo V; Vitale G; Russo D; Palomba S; Nappi C
    J Endocrinol Invest; 1997 Sep; 20(8):493-6. PubMed ID: 9364254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome.
    Zacchè MM; Caputo L; Filippis S; Zacchè G; Dindelli M; Ferrari A
    Gynecol Endocrinol; 2009 Aug; 25(8):508-13. PubMed ID: 19551544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ovarian morphology and prevalence of polycystic ovary syndrome in reproductive aged women with or without mild acne.
    Kelekci KH; Kelekci S; Incki K; Ozdemir O; Yilmaz B
    Int J Dermatol; 2010 Jul; 49(7):775-9. PubMed ID: 20618496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What is the preferred GnRH analogue for polycystic ovary syndrome patients undergoing controlled ovarian hyperstimulation for in vitro fertilization?
    Orvieto R; Meltcer S; Homburg R; Nahum R; Rabinson J; Ashkenazi J
    Fertil Steril; 2009 Apr; 91(4 Suppl):1466-8. PubMed ID: 18774558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ovarian hyperstimulation after administration of triptorelin therapy to a patient with polycystic ovary syndrome.
    Campo S; Bezzi I; Garcea N
    Fertil Steril; 2000 Jun; 73(6):1256-8. PubMed ID: 10856495
    [No Abstract]   [Full Text] [Related]  

  • 7. [Polycystic ovary. The PCO syndrome].
    Goldenstein S; Sillem M
    Med Monatsschr Pharm; 2002 Jul; 25(7):233-5. PubMed ID: 12148236
    [No Abstract]   [Full Text] [Related]  

  • 8. Prevalence of polycystic ovary syndrome in girls aged 14-18 years in Isfahan, Iran.
    Hashemipour M; Faghihimani S; Zolfaghary B; Hovsepian S; Ahmadi F; Haghighi S
    Horm Res; 2004; 62(6):278-82. PubMed ID: 15523185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physiological estrogen replacement may enhance the effectiveness of the gonadotropin-releasing hormone agonist in the treatment of hirsutism.
    Carmina E; Janni A; Lobo RA
    J Clin Endocrinol Metab; 1994 Jan; 78(1):126-30. PubMed ID: 8288696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacologic treatment of polycystic ovary syndrome.
    Ehrmann DA; Rychlik D
    Semin Reprod Med; 2003 Aug; 21(3):277-83. PubMed ID: 14593550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cutaneous Findings and Systemic Associations in Women With Polycystic Ovary Syndrome.
    Schmidt TH; Khanijow K; Cedars MI; Huddleston H; Pasch L; Wang ET; Lee J; Zane LT; Shinkai K
    JAMA Dermatol; 2016 Apr; 152(4):391-8. PubMed ID: 26720591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hormonal therapy for acne: why not as first line therapy? facts and controversies.
    Katsambas AD; Dessinioti C
    Clin Dermatol; 2010; 28(1):17-23. PubMed ID: 20082945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regression of Polycystic Ovaries by Estrogen Therapy.
    Gambrell RD
    Obstet Gynecol; 1976 May; 47(5):569-74. PubMed ID: 131262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with a gonadotropin-releasing hormone agonist in acne or idiopathic hirsutism.
    Faloia E; Filipponi S; Mancini V; Morosini P; De Pirro R
    J Endocrinol Invest; 1993 Oct; 16(9):675-7. PubMed ID: 8282961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effects of cyproterone acetate or a long-acting gonadotropin-releasing hormone agonist in polycystic ovarian disease.
    Couzinet B; Le Strat N; Brailly S; Schaison G
    J Clin Endocrinol Metab; 1986 Oct; 63(4):1031-5. PubMed ID: 2943752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polycystic ovary syndrome (PCOS) trilogy: a translational and clinical review.
    Mason H; Colao A; Blume-Peytavi U; Rice S; Qureshi A; Pellatt L; Orio F; Atkin SL
    Clin Endocrinol (Oxf); 2008 Dec; 69(6):831-44. PubMed ID: 18616705
    [No Abstract]   [Full Text] [Related]  

  • 17. Oral contraceptive therapy for polycystic ovary disease after chronic gonadotropin-releasing agonist administration. Predictors of continued ovarian suppression.
    Elkind-Hirsch KE; Anania C; Malinak R
    J Reprod Med; 1996 Sep; 41(9):645-52. PubMed ID: 8887188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acne severity and the Global Acne Grading System in polycystic ovary syndrome.
    Hacivelioglu S; Gungor AN; Gencer M; Uysal A; Hizli D; Koc E; Cosar E
    Int J Gynaecol Obstet; 2013 Oct; 123(1):33-6. PubMed ID: 23948280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hirsutism and acne treated by an androgen antagonist.
    Nelson RM; Rakoff AE
    Obstet Gynecol; 1970 Nov; 36(5):748-52. PubMed ID: 4248736
    [No Abstract]   [Full Text] [Related]  

  • 20. Use of nafarelin to investigate the pathophysiology of the polycystic ovary syndrome.
    Shaw RW
    J Reprod Med; 1989 Dec; 34(12 Suppl):1039-43. PubMed ID: 2533620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.